New hope for lupus sufferers: targeted drug trial targets stubborn symptoms
NCT ID NCT07381465
First seen Feb 02, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study tests a new drug called Firsekibart in 15 adults with mild to moderate lupus that hasn't improved with usual treatments. The drug blocks a protein involved in inflammation, aiming to reduce lupus symptoms like fever and organ inflammation. Researchers will check if patients improve after 12 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.